Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Arrowhead Pharma
(NQ:
ARWR
)
23.17
+0.55 (+2.43%)
Official Closing Price
Updated: 4:15 PM EDT, May 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Arrowhead Pharma
< Previous
1
2
3
4
5
Next >
Arrowhead Announces Positive Interim Results from Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
July 06, 2021
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pauses ARO-ENaC Phase 1/2 Clinical Study
July 02, 2021
From
Arrowhead Pharmaceuticals Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-ANG3 for Treatment of Mixed Dyslipidemia
June 30, 2021
From
Arrowhead Pharmaceuticals Inc.
Via
Business Wire
Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment in Patients with Alpha-1 Liver Disease at EASL International Liver Congress
June 26, 2021
From
Arrowhead Pharmaceuticals Inc.
Via
Business Wire
Arrowhead Presents Preclinical Data on ARO-DUX4 at FSHD Society International Research Congress
June 25, 2021
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver Congress
June 23, 2021
From
Arrowhead Pharmaceuticals Inc.
Via
Business Wire
Arrowhead Pharmaceuticals and Horizon Therapeutics Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout
June 21, 2021
From
Arrowhead Pharmaceuticals, Inc. and Horizon Therapeutics plc
Via
Business Wire
Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-APOC3 for Treatment of Severe Hypertriglyceridemia
June 03, 2021
From
Arrowhead Pharmaceuticals Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
June 02, 2021
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Earns $10 Million Option Exercise Fee
May 18, 2021
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
May 12, 2021
From
Arrowhead Pharmaceuticals Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Reports Fiscal 2021 Second Quarter Results
May 04, 2021
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Announces Improvement in Fibrosis after ARO-AAT Treatment in Patients with Alpha-1 Liver Disease
April 28, 2021
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results
April 16, 2021
From
Arrowhead Pharmaceuticals Inc.
Via
Business Wire
Arrowhead Announces ARO-DUX4 as First Muscle Targeted RNAi Candidate Using TRiMTM Platform
April 15, 2021
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.